Phase 3Data readout

Pegozafermin (BIO89-100) (FGF21 analog)

metabolic dysfunction-associated steatohepatitis

ETNB89bio Inc.

Expected catalystJune 30, 2027Company guidance: Jun 30, 2027

Catalyst overview

Event details

Drug or asset: Pegozafermin (BIO89-100) (FGF21 analog)
Development stage: Phase 3
Event type: Data readout
Indication: metabolic dysfunction-associated steatohepatitis

Research summary

What is being tracked?

This catalyst tracks a Phase 3 data readout for Pegozafermin (BIO89-100) (FGF21 analog) in metabolic dysfunction-associated steatohepatitis . The expected timing is based on the latest available company guidance and may change.

Development notes

ENLIVEN, ENLIGHTEN trials. 3/12/24- Initiated ENLIGHTEN-Fibrosis trial. 3/27/24- Granted EMA PRIME status. 5/14/24- Initiates ENLIGHTEN-Cirrhosis trial. 11/15/25- New analysis at AASLD'24. 8/7/25- Topline data in H1 2027 and 2028. 10/30/25- RHHBY acquired ETNB.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source